Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter 2013
Date:8/6/2013

er.  Our recent successful stock offering provides us with the cash we need to develop ISIS-APOCIIIRx through Phase 3 development on our own.  Already this year, we reported positive Phase 2 data from ISIS-APOCIIIRx in two separate Phase 2 studies in patients with high triglycerides.
In these studies, we observed positive effects on apoC-III, triglycerides, overall lipid parameters and other measures of activity.  These data show that ISIS-APOCIIIRx can be used as a monotherapy or in combination with other triglyceride-lowering drugs with the potential to positively impact the lives of patients with severely high triglycerides.  We plan to report the third set of data later this month and initiate the Phase 3 program for ISIS-APOCIIIRx early next year after discussions with the FDA and European regulators," concluded Ms. Parshall.

Drug Development Highlights

  • Isis and its partners advanced antisense drugs in Isis' pipeline and reported positive clinical data from three programs.
  • Isis advanced the Phase 2/3 study of ISIS-TTRRx, a drug to treat patients with familial amyloid polyneuropathy.  As a result, Isis earned $2 million from GlaxoSmithKline.
  • Isis reported Phase 2 data on ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable fibrates.  In this study, ISIS-APOCIIIRx treatment resulted in statistically significant reductions in triglycerides and apoC-III and a statistically significant increase in HDL.
  • Isis reported Phase 2 data on ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes at the American Diabetes Association Scientific Sessions.  In this study, ISIS-APOCIIIRx treatment resulted in statistically significant reductions in triglycerides and apoC-III and a statistically significant increase in high-density lipoprotein (HDL).  In this
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. CVS Caremark Reports Record Second Quarter Results
    2. BioLineRx Reports Second Quarter 2013 Results
    3. Regeneron Reports Second Quarter 2013 Financial and Operating Results
    4. Cytos Biotechnology Ltd Reports Second Quarter 2013 Financial Results and Recent Developments
    5. Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis
    6. Landauer, Inc. Reports Fiscal 2013 Third Quarter Results
    7. PDI Reports 2013 Second Quarter Financial Results
    8. U.S. Orthopedic Biomaterials Market & Global Biomaterials Industry Reviewed by Products and Applications in New Research Reports
    9. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
    10. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
    11. Neuland Labs Reports First Quarter Fiscal Year 2014 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/29/2015)... Israel , June 29, 2015 ... today announced positive preliminary results from its BVX-006 Phase ... universal influenza vaccine. In this trial, M-001 was injected ... 65, followed by an administration of the 2014/15 season ... found to be safe and well tolerated and induced ...
    (Date:6/29/2015)... , June 29, 2015 Regeneron ... that the Proceedings of the National Academy ... demonstrating that the Company,s proprietary VelociGene ® ... identification and preclinical validation of potential candidates that ... of Middle East Respiratory Syndrome (MERS). This involved ...
    (Date:6/29/2015)... , June 29, 2015 The global ... by 2020, according to a new study by Grand View Research, ... and the presence of high unmet needs in emerging markets such ... are expected to be two of the most significant growth ... diseases such as obesity and growing global geriatric population base are ...
    Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 2Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 4Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 5Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 2Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 3Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 4
    ... 2011 Merrimack Pharmaceuticals, Inc. announced today that ... randomized Phase 2 clinical trial of MM-121, a ... with paclitaxel (Taxol®) in the neoadjuvant setting of ... The Phase 2 study is designed ...
    ... Calif., Oct. 11, 2011 Codexis, Inc. (Nasdaq: ... has been named Director, Latin America. He will head ... for managing Codexis, expanding role in Latin America. He ... and SVP, Process Development and Manufacturing. ...
    Cached Medicine Technology:Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients 2Codexis Names Veteran Chemical Executive to Lead Codexis do Brasil 2Codexis Names Veteran Chemical Executive to Lead Codexis do Brasil 3
    (Date:6/29/2015)... ... June 30, 2015 , ... Leaders ... one of the industry’s premier thought leadership symposiums, “Harmony 2015” hosted by Massachusetts-based ... rehabilitation managers and other management and corporate personnel representing the skilled nursing and ...
    (Date:6/29/2015)... ... June 30, 2015 , ... The United States Equestrian ... (KORT) as it becomes the Official Physical and Occupational Therapists of the U.S. Eventing ... Kentucky Three-Day Event presented by Land Rover. , “The USEF is pleased to ...
    (Date:6/29/2015)... ... June 30, 2015 , ... With thousands of children in ... in a much-needed autism support center, planned at Utah Valley University, in Orem, Utah. ... for the center and the building in which it will be housed. , Utah ...
    (Date:6/29/2015)... (PRWEB) , ... June 30, 2015 , ... ... training, has released a new website intended for executives and administrators with hospitals, ... user experience, and the final product is a result of comprehensive research and ...
    (Date:6/29/2015)... ... June 29, 2015 , ... ... to educate readers and potential patients about a variety of plastic surgery and ... dentistry and more. , It has been the main focus of Cosmetic Town ...
    Breaking Medicine News(10 mins):Health News:Gov. Mark Parkinson, President and CEO of AHCA/NCAL to Give Keynote Address at Harmony 2015 2Health News:Gov. Mark Parkinson, President and CEO of AHCA/NCAL to Give Keynote Address at Harmony 2015 3Health News:KORT Physical Therapy Announces Partnership with The United States Equestrian Federation 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Career Step Launches New Website to Better Meet Needs of Partners, Clients and Others Searching for Corporate Training Solutions 2Health News:Board of Advisors Now Coming to Cosmetic Town 2
    ... that exposure to a chemical called diacetyl, a component ... nose and airways of mice. Scientists at the National ... National Institutes of Health, conducted the study because diacetyl ... humans. OB is a debilitating but rare lung disease, ...
    ... University of Leicester has been able to establish for ... may have miscarriages and those who wont. Their research ... American Medical Association. , The researchers measured the levels ... anandamide in women who presented with a threatened miscarriage ...
    ... For accuracy,s sake, medical professionals should use the ... images taken from different time periods and laboratories, ... collaborative study, published in the January-February issue of ... researchers at Sacred Heart Medical Center in Eugene, ...
    ... mimicked a tumor of the pancreas and the diagnosis was ... pancreatectomy. , This report performed by a team led by ... to be published in Volume 14 issue 6 of the ... age of patient, and on the localization, size and shape ...
    ... Insurers Strengthens its ... Patients, BERKELEY HEIGHTS, N.J., March 13 ... provider of secure workflow,management software and web-based services, ... leading mobility benefit providers to,national and regional insurers ...
    ... America Launches ,Treat It, Don,t Repeat ... Educational Campaign -, WASHINGTON, March 13 More ... their condition has,a negative impact on important relationships -- ... to a new national survey commissioned by the,Anxiety Disorders ...
    Cached Medicine News:Health News:Rodent study finds artificial butter chemical harmful to lungs 2Health News:Leicester medical team announces 'predictor' for pregnant women who may have miscarriages 2Health News:Leicester medical team announces 'predictor' for pregnant women who may have miscarriages 3Health News:Researchers make case for standardized analysis of cardiac imaging 2Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 2Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 3Health News:Wheelchair Professionals Selects Authentidate's Inscrybe Healthcare Platform to Streamline Mobility Order Processing 4Health News:Video: New Survey Reveals More Than Half of Adults With OCD Say the Disorder Has a Negative Impact on Relationships at Home, Work and in Their Personal Life 2Health News:Video: New Survey Reveals More Than Half of Adults With OCD Say the Disorder Has a Negative Impact on Relationships at Home, Work and in Their Personal Life 3
    For regulating sample flow rate when using the QIAvac 24 Plus;...
    For processing mini spin columns on QIAvac 24;...
    DNA/RNA preparation in 8-multi channels...
    ... Filter Units,Filter units with hydrophobic PTFE ... membrane are ideal for the sterilizing ... sterile containers, and for sterilizing or ... mm Millex filter units are available ...
    Medicine Products: